1Brahmer JR,Tykodi SS,Chow LQ,et al. Safety and activ- ity of anti-PDL1 antibody in patients with advanced canc- er[J]. N Engt J Med,2012,366(26) :2455-2465.
2Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity[J]. Immunol Rev, 2010, 236(1) :219-242.
3Okazaki T, Honjo T. The PD-1/PD-L pathway in immu- nological tolerance [J]. Trends Immunol, 2006, 27 ( 4 ) : 195-201.
4Sun H, Sun C,Xiao W. Expression regulation of co-inhibi- tory molecules on human natural killer ceils in response to cytokine stimulations[J]. Cytokine, 2014,65 ( 1 ) : 33-41.
5Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Pro- grammed death-1 pathway in cancer and autoimmunity [J]. Clin Immunol, 2014,153 (1) : 145-152.
6Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med,2012,366(26) :2443-2454.
7Park HJ, Kusnadi A, Lee EJ, et al. Tumor-infiltrating reg- ulatory T cells delineated by upregulation of PD-1 and in- hibitory receptors[J]. Cell Immunol, 2012,278 ( 1/2 ) : 76- 83.
8Janakiram ML,Abadi YM,Sparano JA,et al. T cell coinh- ibition and immunotherapy in human breast cancer[J]. Discov Med, 2012,14(77) : 229-236.
9Sendur MA, Aksoy S,Demirci S, et al. Can targeted pro- grammed death-1 antibody be a new treatment approach in breast cancer[J]. J BUON,2014,19(2) :584.
10Ghebeh H,Tulbah A,Mohammed S, et al. Expression of PD-L1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells[J]. Int J Cancer,2007,121(4) :751-758.
